TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7340890
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg once daily
Study: 27059799
Drug: Clazakizumab 100
Normalized name: Clazakizumab
DrugBank: Clazakizumab (DB12849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazakizumab 100 mg
Study: 27059799
Drug: Clazakizumab 25
Normalized name: Clazakizumab
DrugBank: Clazakizumab (DB12849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazakizumab 25 mg
Study: 27059799
Drug: Clazakizumab 200
Normalized name: Clazakizumab
DrugBank: Clazakizumab (DB12849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazakizumab 200 mg
Study: 27059799
Drug: Clazakizumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazakizumab (all doses)
Study: 22507276
Drug: Two-strain combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-strain combination probiotic (Lactobacillus acidophilus and Bifidobacterium bifidum) given twice a day for 3 months
Study: 22507276
Drug: Placebo given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given twice a day for 3 months
Study: 22507276
Drug: Two-strain combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-strain combination probiotic
Study: 18628618
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg/day) for 14 days
Study: 18628618
Drug: L-arginine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (500 microM)
Study: 18628618
Drug: L-N(5)-(I-iminoethyl)ornithine (NOS
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-N(5)-(I-iminoethyl)ornithine (NOS inhibitor)
Study: 11315826
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker (amlodipine)
Study: 8722437
Drug: Alpha-adrenergic blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-adrenergic blocker (doxazosin)
Study: 9326656
Drug: Oral pyrimidine
Normalized name: 4'-Hydroxypyrazolol(3,4-d)pyrimidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pyrimidine nucleoside or nucleotide compounds
Study: 21356082
Drug: Micronutrients capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrients capsule (zinc 30 mg, selenium 70 μg, vitamin A 400 μg, alpha-tocopherol 30 mg, vitamin C 200 mg, niacin 100 mg)
Study: 19245076
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment in a hyperbaric chamber
Study: 11672947
Drug: Social distribution
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social distribution of drug use
Study: 9039532
Drug: High-dose clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose clarithromycin (1,000 mg or 750 mg b.i.d.)
Study: 9039532
Drug: Low-dose clarithromycin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose clarithromycin (1,000 mg or 750 mg q.d.)
Study: 8176095
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of atenolol once a day
Study: 8176095
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of controlled-release metoprolol once a day
Study: 3283918
Drug: Al-Mg antacids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Al-Mg antacids (one tablet four times daily; acid-neutralizing capacity, 120 mmol/day) + pirenzepine (50 mg twice daily)
Study: 3283918
Drug: Al-Mg antacids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Al-Mg antacids (one tablet four times daily; acid-neutralizing capacity, 120 mmol/day) + pirenzepine placebo
Study: 3283918
Drug: Antacid placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid placebo + pirenzepine (50 mg twice daily)
Study: 3283918
Drug: Antacid placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid placebo + pirenzepine placebo
Study: 3283918
Drug: Antacid placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid placebo
Study: 28069089
Drug: Test meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test meal with 19-mg (all-E)-LYC from tomato paste
Study: 28069089
Drug: Test meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test meal with 19-mg (all-E)-LYC from tomato paste plus 500-mg calcium carbonate
Study: 16611682
Drug: Oral saline
Normalized name: Walgreens Phosphate Oral Saline Laxative SF Solution (Cherry)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral saline hydration (1 g/10 kg of body weight/day for 2 days before the procedure)
Study: 16611682
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline hydration (0.9% saline at a rate of 15 ml/kg for 6 h before the procedure)
Study: 16611682
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline hydration plus theophylline (5 mg/kg per os 1 h before the procedure)
Study: 16611682
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline hydration plus furosemide (3 mg/kg intravenously just after the procedure)
Study: 15478160
Drug: Glucosamine sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulfate (maximum 1,500 mg/day)
Study: 11505880
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose dexamethasone (100 mg stat, 16 mg every 6 hours for 48 hours)
Study: 320955
Drug: Nonspecific therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonspecific therapy
Study: 24708480
Drug: Melatonin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (50 mg infusion intra-operatively, 10 mg orally for the first three nights post-surgery)
Study: 22285168
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg per day
Study: 22285168
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (cisplatin 75 mg/m2 plus docetaxel 75 mg/m2 or gemcitabine 1250 mg/m2)
Study: 17639157
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of multimixture added to school meals
Study: 15778243
Drug: Etanercept treatment
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept treatment for 6 weeks
Study: 15778243
Drug: Etanercept treatment
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept treatment for 24 weeks
Study: 11870097
Drug: Alternative medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative medicine treatments (specific interventions not detailed)
Study: 11870097
Drug: Randomized trials
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized trials of alternative medicine
Study: 8726297
Drug: Mianserin, 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin, 120 mg/day
Study: 1872019
Drug: Yeast recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeast recombinant pre‐S2 + S vaccine (12, 24 or 48 micrograms)
Study: 1872019
Drug: Yeast recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeast recombinant pre‐S2 + S vaccine
Study: 26950692
Drug: Psychoanalytic psychotherapy
Normalized name: PSYCHOANALEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoanalytic psychotherapy (PPT) for 2 years of weekly sessions
Study: 26950692
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) for 5 months
Study: 22458939
Drug: AZD9668 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9668 60 mg bid
Study: 22458939
Drug: AZD9668 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9668 5 mg bid
Study: 22458939
Drug: AZD9668 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9668 20 mg bid
Study: 19543000
Drug: granisetron 1
Normalized name: granisetron 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: granisetron 1 mg
Study: 17380590
Drug: Duloxetine 20
Normalized name: duloxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 20 mg, 40 mg, and 60 mg single doses
Study: 17380590
Drug: Duloxetine 20
Normalized name: duloxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 20 mg and 40 mg twice-daily for 5 days
Study: 17371357
Drug: Topiramate (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (50 mg)
Study: 15450676
Drug: Ketamine (0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.12 mg bolus followed by 0.5 mg/kg over 60 min)
Study: 11408234
Drug: Levofloxacin 750
Normalized name: levofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 750 mg intravenous
Study: 9818104
Drug: 5-HT2 antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5-HT2 antagonist (sarpogrelate hydrochloride, 300 mg a day po)
Study: 9818104
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (5-HT2 antagonist with SGBs)
Study: 772172
Drug: Thioridazine treatment
Normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thioridazine treatment (n=23)
Study: 772172
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (n=22)
Study: 31947853
Drug: Isomaltulose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isomaltulose (50 g)
Study: 25515398
Drug: Sucrose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (50 g)
Study: 30844048
Drug: Non-febuxostat (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-febuxostat (conventional therapy with lifestyle modification)
Study: 28709022
Drug: Dialectical behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical behavior therapy skills-based intervention
Study: 23708056
Drug: L-arginine (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (9 g daily for 6 months)
Study: 21167859
Drug: HB‐AS02 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB‐AS02 vaccine (two doses given one month apart)
Study: 21167859
Drug: Licensed conventional
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Licensed conventional recombinant hepatitis B vaccine (HBVAXPRO™; two doses)
Study: 21167859
Drug: HB‐AS02 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB‐AS02 vaccine (single booster dose)
Study: 21167859
Drug: Licensed conventional
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Licensed conventional recombinant hepatitis B vaccine (single booster dose)
Study: 16368038
Drug: Once-monthly ibandronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-monthly ibandronate 150 mg
Study: 18042311
Drug: Weekly alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly alendronate 70 mg
Study: 14708420
Drug: Oxybutinin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutinin (0.4 mg/kg)
Study: 9310809
Drug: Non-clonidine treatment
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-clonidine treatment
Study: 3881558
Drug: Clonidine treatment
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine treatment
Study: 3753293
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium antagonist (nifedipine)
Study: 3753293
Drug: Intravenous naftidrofuryl
Normalized name: naftidrofuryl
DrugBank: Naftidrofuryl (DB13588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous naftidrofuryl with vitamin A, vitamin E, and zinc
Study: 26588809
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g transdermal testosterone gel (TT) (N = 16)
Study: 26588809
Drug: Anastrozole (AI)
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole (AI) 1 mg (N = 14)
Study: 19851858
Drug: Dose-intensive neoadjuvant
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose-intensive neoadjuvant therapy
Study: 17941031
Drug: Low-dose computed
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose computed tomography (CT) screening for lung cancer
Study: 16188549
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy using BMPs
Study: 11861035
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg 17 beta-estradiol continuously plus sequential progestagen over 1 year
Study: 11861035
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of HRT after 12 months
Study: 2699100
Drug: F XIII
Approvals — FDA: no, EMA: no, PMDA: no
Description: F XIII concentrate treatment
Study: 24081439
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose fish oil (5.5 g/day)
Study: 24081439
Drug: Control (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (low dose fish oil 0.4 g/day)
Study: 23566639
Drug: 2L PEG‐3350
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2L PEG‐3350 and bisacodyl tablets
Study: 15482502
Drug: Social communication
Normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social communication intervention with regular monthly therapist contact for 6 months and 2-monthly consolidation sessions for an additional 6 months.
Study: 9274584
Drug: Ivermectin plus
Normalized name: clorsulon / ivermectin Injectable Solution [Ivermax Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin plus Albendazole (200-400 micrograms/kg ivermectin and 400 mg albendazole)
Study: 10717746
Drug: Albendazole alone
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole alone (400 mg)
Study: 24277961
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam 0.3 mg/kg
Study: 27373358
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (placebo) 2 ml
Study: 25122671
Drug: Masitinib (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Masitinib (12 mg/kg/day)
Study: 25122671
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg/day 4-weeks-on/2-weeks-off)
Study: 20863554
Drug: Cisplatin 50
Normalized name: cisplatin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 50 mg/m² + Doxorubicin 45 mg/m² + G‐CSF 5 μg/kg (CD)
Study: 20863554
Drug: Cisplatin 50
Normalized name: cisplatin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 50 mg/m² + Doxorubicin 45 mg/m² + G‐CSF 5 μg/kg + Paclitaxel 160 mg/m² (CDP)
Study: 18508824
Drug: Cell phone-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell phone-based exercise programme (daily endurance walking at 80% of maximal capacity, adjusted monthly based on ISWT results)
Study: 18508824
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (verbal instructions for daily walking exercise at home)
Study: 17265571
Drug: etoricoxib (≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib (≥ 60 mg/day)
Study: 17265571
Drug: non-naproxen traditional
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: non-naproxen traditional NSAIDs (ibuprofen and diclofenac)
Study: 17265571
Drug: naproxen (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen (1000 mg/day)
Study: 9063785
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg acetaminophen with codeine phosphate and diphenhydramine
Study: 23265352
Drug: L-DOPS co-administered
Normalized name: L-DOPS
DrugBank: Droxidopa (DB06262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-DOPS co-administered with entacapone
Study: 23265352
Drug: L-DOPS alone
Normalized name: L-DOPS
DrugBank: Droxidopa (DB06262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-DOPS alone
Study: 21303529
Drug: Preventive spinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive spinal manipulative therapy (SMT) - 1 monthly session for 10 months
Study: 21303529
Drug: Preventive spinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive spinal manipulative therapy with home exercise program (SMT + exercise) - 1 monthly SMT session combined with home exercises for 10 months
Study: 9874808
Drug: Ibuprofen (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (800 mg)
Study: 19673707
Drug: Acetaminophen/Hydrocodone (650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen/Hydrocodone (650 mg acetaminophen with 10 mg hydrocodone)
Study: 19673707
Drug: Placebo (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (800 mg of lactose)
Study: 15126801
Drug: Bicalutamide 150
Normalized name: bicalutamide 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 150 mg once daily
Study: 11482747
Drug: Tolterodine 2
Normalized name: tolterodine 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 2 mg twice daily for up to 12 months
Study: 9444018
Drug: Praziquantel 5
Normalized name: praziquantel 57 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel 5 mg/kg
Study: 9444018
Drug: Praziquantel 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel 2.5 mg/kg
Study: 9444018
Drug: Mebendazole 800
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mebendazole 800 mg in 10d table salt
Study: 9444018
Drug: Mebendazole 400
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mebendazole 400 mg in 10d table salt
Study: 29199013
Drug: Netarsudil 0.02%
Normalized name: NETARSUDIL 0.02% OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netarsudil 0.02% once daily (q.d.)
Study: 29199013
Drug: Netarsudil 0.02%
Normalized name: NETARSUDIL 0.02% OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netarsudil 0.02% twice daily (b.i.d.)
Study: 30653957
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5% twice a day (b.i.d.)
Study: 24342252
Drug: Alternate dosing
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate dosing schedule (0, 2, 12 months)
Study: 24342252
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing schedule (0, 2, 6 months)
Study: 18315966
Drug: Percutaneous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous treatment of displaced intra-articular calcaneal fractures
Study: 14634366
Drug: Portable device
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Portable device providing extrinsic auditory feedback in gait therapy
Study: 14634366
Drug: Conventional gait
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional gait therapy only
Study: 1746296
Drug: Diet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet and exercise followed by gemfibrozil therapy
Study: 6280794
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose cyclophosphamide alone
Study: 6280794
Drug: Cyclophosphamide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide plus high‐dose methotrexate plus vincristine
Study: 29177407
Drug: Extra early
Normalized name: Panadol Extra
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra early standard dose of measles vaccine (MV) (Edmonston‐Zagreb strain)
Study: 23644703
Drug: Placebo (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5% aqueous dextrose solution)
Study: 17377800
Drug: Morphine intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine intravenous patient‐controlled analgesia (IV PCA)
Study: 15705921
Drug: LT4 monotherapy
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LT4 monotherapy (n = 48)
Study: 12730320
Drug: Model predicting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model predicting mortality based on two or more activities of daily living (ADLs) difficulty
Study: 1940094
Drug: Imipramine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (25 mg/daily)
Study: 6108592
Drug: Nabilone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone (4 or 5 mg)
Study: 6108592
Drug: Nabilone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone (1 or 2 mg)
Study: 6117576
Drug: Nabilone (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone (lower doses)
Study: 31138184
Drug: Norethindrone 5
Normalized name: norethindrone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethindrone 5 mg three times daily
Study: 31138184
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptives (OCP)
Study: 27743908
Drug: Parent-based cognitive
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-based cognitive behavioral therapy
Study: 19349122
Drug: Hybrid cognitive-behavioral
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid cognitive-behavioral therapy (H-CBT)
Study: 15534251
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (5 g per day)
Study: 15649161
Drug: Laser acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser acupuncture on P6 point and saline infusion
Study: 15649161
Drug: Metoclopramide 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 0.1 mg.kg(‐1) i.v. and sham laser
Study: 15649161
Drug: Sham laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham laser and saline infusion
Study: 10578981
Drug: Sialosyl-Tn (STn)
Normalized name: sialyl Lewis A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sialosyl-Tn (STn) monoclonal antibody staining
Study: 9081852
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg ramipril daily
Study: 1847026
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (15,000 UaXa, subcutaneous, daily for 6 months)